Nevro Names Kevin Thornal As Its New CEO; Investors Remain Disappointed In Results
Thornal will replace Keith Grossman who is retiring. Investors and analysts hope Thornal will help the spinal cord stimulation company reach profitability by growing its “core” chronic pain business.
You may also be interested in...
Nevro Attacks Pain And Competition With Individualized AI-Enabled Spinal Cord Stimulator
The company is selling the Senza HFX iQ spinal cord stimulation system across the US following a successful limited market release.
Minute Insight: Abbott Receives US FDA Clearance For Spinal Cord Stimulator
Abbott announced on 19 December that the US Food and Drug Administration has approved its Eterna spinal cord stimulation system (SCS) for treating chronic pain with low-dose BURSTDR stimulation.
Nevro’s HFX Offers Durable Benefit In People Suffering Diabetic Pain
New 24-month data from the SENZA-PDN trial, presented at the American Diabetes Society conference in New Orleans, provides more support for HFX 10 kHz as a reliable therapy for people with painful diabetic neuropathy.